Department of Genetics, Cell- and Immunobiology, Semmelweis University, Nagyvárad Sqr. 4, Budapest 1089, Hungary.
Department of Genetics, Cell- and Immunobiology, Semmelweis University, Nagyvárad Sqr. 4, Budapest 1089, Hungary; Lung Health Hospital, Munkácsy Mihály Str. 70, Törökbálint 2045, Hungary.
Immunol Allergy Clin North Am. 2020 Feb;40(1):1-14. doi: 10.1016/j.iac.2019.09.009. Epub 2019 Nov 6.
Allergen immunotherapy (AIT) is considered to be the only treatment option with the promise of healing and induction of long-lasting allergen tolerance, persisting even after discontinuation of therapy. Despite a more than 100-year-long history, still only a minority of patients are being treated with AIT. Substantial developments took place in the last decade to overcome problems in standardization, efficacy, safety, high costs, long duration of treatment; and new guidelines have also been implemented. Major advancements in the understanding of AIT mechanisms with the focus on recent findings of subcutaneous and sublingual AIT have been summarized.
变应原免疫治疗(AIT)被认为是唯一具有治愈和诱导长期过敏原耐受作用的治疗选择,即使在治疗停止后仍能持续。尽管已有 100 多年的历史,但只有少数患者接受 AIT 治疗。在过去十年中,为克服标准化、疗效、安全性、高成本和治疗时间长等问题取得了重大进展;并实施了新的指南。总结了对 AIT 机制的理解的重大进展,重点是皮下和舌下 AIT 的最新发现。